PMID- 24769529
OWN - NLM
STAT- Publisher
LR  - 20191120
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 48
IP  - 8
DP  - 2014 Aug
TI  - Pregabalin-Associated Heart Failure Decompensation in a Patient With a History of 
      Stage I Heart Failure.
PG  - 1077-1081
AB  - OBJECTIVE: To describe an elderly male patient with a prior history of New York 
      Heart Association (NYHA) class I heart failure (HF) who presented with cardiac 
      decompensation related to pregabalin therapy and to review the literature 
      involving the effects of pregabalin in HF patients. CASE SUMMARY: An 84-year-old 
      man with NYHA class I HF (left-ventricular ejection fraction between 45% and 50%) 
      presented to the emergency department with acute HF decompensation approximately 
      10 days after initiation of pregabalin for the management of peripheral 
      neuropathy. Discontinuation of pregabalin and administration of furosemide 
      resulted in resolution of symptoms. Shortness of breath; facial, neck, and 
      peripheral edema; and weight gain all improved within 2 days. Three months 
      following discontinuation of furosemide and pregabalin, the patient remained 
      stable without any recurring symptoms or progression in HF. DISCUSSION: 
      Pregabalin is associated with a 10% to 15% prevalence of peripheral edema and 
      weight gain, with cases reported in patients both with and without HF. Whereas 
      most reported HF exacerbations have occurred in patients with NYHA class II to IV 
      HF, this case is one of the first to be reported in a patient with NYHA class I. 
      According to the Naranjo probability scale (score of 4), it was possible that the 
      patient's HF symptoms were related to pregabalin. The mechanism of action of 
      pregabalin-induced HF is unknown, but pregabalin has been shown to act as a 
      calcium channel antagonist. CONCLUSION: Although further studies are needed, this 
      case suggests that close monitoring of patients with NYHA class I HF should be 
      considered when initiating pregabalin therapy.
CI  - (c) The Author(s) 2014.
FAU - Fong, Taryn
AU  - Fong T
AD  - University of the Pacific, Stockton, CA, USA.
FAU - Lee, Audrey J
AU  - Lee AJ
AD  - University of the Pacific, Stockton, CA, USA Department of Veterans Affairs, San 
      Francisco, CA, USA alee@pacific.edu.
LA  - eng
PT  - Journal Article
DEP - 20140425
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
OTO - NOTNLM
OT  - cardiology
OT  - clinical pharmacy
OT  - congestive heart failure
OT  - drug-induced disorders
OT  - pain management
EDAT- 2014/04/29 06:00
MHDA- 2014/04/29 06:00
CRDT- 2014/04/29 06:00
PHST- 2014/04/29 06:00 [entrez]
PHST- 2014/04/29 06:00 [pubmed]
PHST- 2014/04/29 06:00 [medline]
AID - 1060028014530551 [pii]
AID - 10.1177/1060028014530551 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2014 Aug;48(8):1077-1081. doi: 10.1177/1060028014530551. Epub 
      2014 Apr 25.